Cadrenal Therapeutics, Inc. · NASDAQ:CVKD
Cadrenal Therapeutics — Investor Presentation (September 2026)
21 slides from Cadrenal Therapeutics's investor presentation, September 2026
Slide 1: Strategic Partnering Opportunity
Strategic Partnering Opportunity Advancing High-value Cardiac Acute Critical Care & Orphan Disease Drug Assets September 2026 Nasdaq: CVKD 3 >$3B Orphan Drug Total Peak Designations Annual Revenue (FDA) Potential
Slide 2: Forward-looking Statements
Forward-looking Statements This document contains forward-looking statements. In addition, from time to time, we or our representatives may make forward-looking statements orally or in writing. We base these forward-looking statements on our expectations and projections about future events, which we
Slide 3: Company Overview & Strategy
Company Overview & Strategy Advancing late-stage portfolio with peak annual revenue potential in excess of $3 billion while pursuing partnering opportunities for cardiac acute critical care franchise Pillars of CardiacWho Acute WeCritical are Care Franchise Program Advancement Priorities 1 2 3 Pre-O
Slide 4: Late-Stage Pipeline with Defined Regulatory Pathways
Late-Stage Pipeline with Defined Regulatory Pathways For strategic partners with acute care/ICU franchises or rare immunothrombotic conditions Franchise Candidate MOA Indication Regulatory Preclinical Phase I Phase II Phase III • FDA Orphan Drug Designation (ODD) HIT • EMA Orphan Drug CAD-1005 12-LO
Slide 5: CAD-1005 (onvoloxastat)
CAD-1005 (onvoloxastat) Highly-selective first-in-class, small-molecule (IV) 12-LOX inhibitor 5
Slide 6: CAD-1005 Overview
CAD-1005 Overview The only selective 12-LOX inhibitor in clinical trials with CSA-AKI and HIT as lead indications What is 12-LOX and why is it important in HIT ? • 12-LOX is an enzyme primarily expressed in platelets that amplifies FcγRIIa-mediated platelet activation • In HIT, 12-LOX is a critical
Slide 7: The 12-LOX Platform Opportunity
The 12-LOX Platform Opportunity Potential for a robust pipeline that targets an immuno-inflammatory driver of life-threatening conditions and represents several billion-dollar markets 12-Lipoxygenase (12-LOX): Key Enzyme in Immuno-Inflammatory Signaling 12-LOX is a key enzyme in immuno-inflammatory
Slide 8: Potential Clinical Applications for Targeted 12-LOX Inhibition
Potential Clinical Applications for Targeted 12-LOX Inhibition Based on current 12-LOX clinical data and supportive preclinical evidence in the literature Cadrenal CAD-1005 development priorities CAD-2000 (oral) pre-clinical candidate for chronic diseases 8
Slide 9: Phase 2 Proof-of-Concept Study
Phase 2 Proof-of-Concept Study CAD-1005 in CSA-AKI (Cardiac Surgery-Associated Acute Kidney Injury) PLUS additional data supporting validation of HIT indication Design: Randomized, blinded, placebo-controlled, parallel group; 1:1:1 CAD-1005 (low-dose, high dose) vs. Placebo Population: High-Risk Pat
Slide 10: Planned Phase 3 Pivotal Study – CAD-1005 in HIT
Planned Phase 3 Pivotal Study – CAD-1005 in HIT Focus on clinically meaningful thrombotic events Design: Randomized, blinded, placebo-controlled, parallel group; 1:1 CAD-1005 vs. Placebo: background SOC Population: suspected HIT; enroll ~180 to yield ~120 Serotonin Release Assay (SRA+) for primary a
Slide 11: Tecarfarin
Tecarfarin “Next-Gen” VKA for difficult-to-manage patients requiring chronic anticoagulation 11
Slide 12: A Multi-Billion-Dollar U.S. Opportunity
A Multi-Billion-Dollar U.S. Opportunity Addressing gaps in the $2B orphan and high-risk “No-DOAC” Zones $38B Global Oral Anticoagulant (OAC) Market $20B U.S. Market $2B Orphan & High-Risk CV Conditions $6B Venous Thromboembolism $18B $20B • 145K ESKD+AFib patients No clinically proven OAC ROW USA
Slide 13: Poorly Controlled Anticoagulation – A Two-Edged Sword
Poorly Controlled Anticoagulation – A Two-Edged Sword Purpose Prevent pathological clot formation Clotting events Bleeding events result in adverse lead to worse outcomes, with Therapeutic range outcomes, require substantial costs additional healthcare resources, and MI Too little Consequences of To
Slide 14: Tecarfarin - Addressing Treatment Gaps with Warfarin
Tecarfarin - Addressing Treatment Gaps with Warfarin Warfarin Tecarfarin MoA • VKA; Hepatic CYP450 metabolism • VKA; Esterase metabolism Target • Widely distributed, not restricted to the liver • Genetic variability in enzyme levels Considerations • No variability due to CYP2C9 polymorphisms DDIs •
Slide 15: EMBRACE-AC Phase 2/3 Study
EMBRACE-AC Phase 2/3 Study Tecarfarin vs. Warfarin in Patients Requiring Chronic Anticoagulation Trial Design • Multi-center, randomized, double-blind - Tecarfarin vs. warfarin Tecarfarin more effective than • 607 patients with indications for chronic anticoagulation. optimally managed warfarin in c
Slide 16: Tecarfarin Maintains Consistent Exposure in Stage 4 CKD Trial
Tecarfarin Maintains Consistent Exposure in Stage 4 CKD Trial Tecarfarin exposure remains stable while warfarin levels significantly increase; Higher levels + longer half life = Higher bleeding risk AUC t1/2 50 25 Percent Increase/Decrease 45 20 40 44 20 Percent Increase in 15 Drug Exposure for Perc
Slide 17: Frunexian
Frunexian Parenteral (intravenous) Factor XIa inhibitor with a fast-on / fast-off profile for acute care use 17
Slide 18: Frunexian: First & Only IV for Acute Care Periprocedural Usage
Frunexian: First & Only IV for Acute Care Periprocedural Usage Frunexian Acute parenteral FXIa inhibitor • Potent (> 95%) XIa inhibition Frunexian Path Forward: • Effective blockade of contact activation • Regulatory: ODD application prepared • Predictable PK/PD • Clinical: Phase 2 planning • Parent
Slide 19: Experienced Leadership
Experienced Leadership From securing undervalued assets to advancing orphan drug development Quang X. Pham Steven Zelenkofske, DO Jeff Cole John Sharp CEO & CBO, Chairman Chief Medical Officer (Fractional) Chief Operating Officer Chief Financial Officer (Interim) John R. Murphy Lee Golden, MD Glynn
Slide 20: Executive Summary – Strategic Value Proposition
Executive Summary – Strategic Value Proposition Flexible partnering structures to differentiated late-stage platforms with high critical care & rare disease commercial potential, defined regulatory pathways, and near-term value creation Aligned Portfolio: Late-stage, de-risked portfolio supporting c
Slide 21: Contact
Contact: Quang X. Pham CEO & Chief Business Officer quang.pham@cadrenal.com Corporate Investor Relations: Robert Blum, Managing Partner Lytham Partners CVKD@lythampartners.com 21
Cadrenal Therapeutics — Investor Presentation (September 2026) on 6ix